

BOARD OF DIRECTORS

Samuel Arce, MD, FAFP

Chairman
Family Physician and Attending Physician
Jamaica Hospital Medical Center, Jamaica, NY

Elena Rios, MD, MSPH

President & CEO
National Hispanic Medical Association,
Washington, DC

Judith Flores, MD, FACP, CHQM

Chairwoman-Elect
Clinical Associate Professor, New York University
School of Medicine, New York, NY

Ana Maria Lopez, MD, MPH, FACP

Secretary
Associate Vice President for Health Equity and
Inclusion, University of Utah Health Sciences
Center, Director of Cancer Health Equity, Huntsman
Cancer Institute, Professor of Medicine, University
of Utah School of Medicine, Salt Lake City, Utah

Nelson Reyneri

Treasurer
Vice President, Sales and External Affairs,
Liberty Power, Fort Lauderdale, FL

Katherine A. Flores, MD

Immediate-Past Chairwoman
Director, UCSF-Fresno, Latino Center for
Medical Education & Research, Fresno, CA

David Carlisle, MD, PhD

President and CEO
Charles R. Drew University of Medicine
& Biomedical Sciences, Los Angeles, CA

Nerieda Correa, MD

Eastchester Medical Associates, PC, Bronx, NY

Efrain Fuentes, EdD

Vice-President, Talent Acquisition,
AltaMed Health Services, Los Angeles, CA

Jorge A. Girotti, PhD, MA

*Associate Dean and Director, Special Curricular
Programs, Admissions, Hispanic Center of Excellence*
Assistant Professor, Medical Education,
UIC College of Medicine, Chicago IL

Paloma Hernandez, MPH

President and CEO
Urban Health Plan, Inc., Bronx, New York

Antonio Linares, MD

*Medical Director and Regional VP, Anthem Blue Cross,
Health & Wellness Solutions, Indianapolis, IN*

Flavia E. Mercado, MD

*Medical Director, Inovalon, Inc.
Adjunct Professor, Snelville, GA*

Norma Gomez Parra, MD

Medical Director, Centromed, San Antonio, TX

Jorge G. Puente, MD

Managing Partner,
Pleasanton Pharma Ventures, Northport, NY

Diana Ramos, MD, MPH

*Director, Reproductive Health, Los Angeles County
Public Health, Laguna Beach, CA*

Ilan Shapiro, MD, FACP

*Chairman, NHMA Council of Young Physicians
General Pediatrics / International
Health Policy Advisor, Fort Myers, FL*

Victor Cueto, MD

*Chairman, NHMA Council of Residents
Resident Physician, Internal Medicine & Pediatrics,
Jackson Memorial Hospital, University of Miami,
Miller School of Medicine, Hialeah, FL*

Abner Murray

*Latino Medical Student Association
MD/PhD Candidate, Steinmetz Laboratory,
Department of Biomedical Engineering,
Department of Molecular Biology and Microbiology,
Molecular Virology Program
Case Western Reserve University, Cleveland, OH*

ADVISORY COUNCIL

Richard H. Carmona, MD, MPH, FACS

*17th US Surgeon General (2002-2006)
Vice Chairman, Canyon Ranch Institute
Distinguished Professor, Zuckerman College of
Public Health, University of Arizona, Tucson, AZ*

Henry Cisneros

Chairman, CityView, San Antonio, TX

Ivelisse Estrada

*Senior Vice President for Corporate and
Community Relations, Univision, Los Angeles, CA*

Linda Griego

President & CEO, Griego Enterprises, Inc., Los Angeles, CA

Yasmine Winkler

*Senior VP Innovation and Productivity
United HealthCare, Chicago, IL*

Richard Zapanta, MD

Orthopedic Surgeon, Monterey Park, CA



February 2, 2016

The Honorable Mitch Greenlick
Chair, House Committee on Health Care
Oregon House of Representatives

The Honorable Rob Nosse
Oregon House of Representatives

Re: Support for HB 4105

Dear Representatives Greenlick and Nosse:

On behalf of the Board of Directors of the National Hispanic Medical Association we urge support for HB 4105 regarding substitution of biological drug products.

HB 4105 would (1) authorize a pharmacist to substitute an alternative biological product when filling a prescription for a prescribed biological product if the alternative biological products is designated as interchangeable with the reference product and (2) provide physicians with access to information regarding specific biological products dispensed to their patients.

We recognize the rising use of biologics and biosimilars in our population now aging with increased chronic disease. Biosimilars go through an extensive review process and manufacturers are required to submit immense studies and data demonstrating a products' efficacy and ensuring it is safe for use by consumers. A pathway for biosimilar regulation in the U.S. was established as a provision of the 2008 Patient Protection and Affordable Care Act (ACA) and in 2012 the FDA issued draft guidelines for biosimilars and a list of biosimilars and interchangeable biological products.

In summary, the National Hispanic Medical Association recommends your support for HB 4105 to clarify the procedures for biosimilar substitution for biologic treatments in a way that increases safety for the patient. We are especially supportive since this bill will provide increased access to quality treatment for Hispanics and all persons in Oregon with chronic diseases.

Sincerely,

A handwritten signature in black ink that reads 'Elena Rios'.

Elena Rios, MD, MSPH
President & CEO

cc: Members, House Committee on Health